Novoste Sees More Beta-Cath Placements, Looks To Exploit First Mover Lead
This article was originally published in The Gray Sheet
Novoste Corp. expects to place 220-280 Beta-Cath brachytherapy systems in top U.S. centers by the end of 2001, an increase from the company's previous guidance of 180-250 placements for the year.
You may also be interested in...
Novoste Corp. is considering further evaluation of its Beta-Cath radiation system using a longer source train and a smaller diameter catheter in conjunction with initial angioplasty treatment.
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.